EC approves subcutaneous formulation of Entyvio for maintenance therapy in adults with Crohn's disease or Ulcerative Colitis

▴ medicircle-ec-approves-entyvio-for-use-in-crohns-disease
Approval makes Entyvio the only maintenance therapy approved across Europe with both intravenous and subcutaneous formulation options for adult patients with ulcerative colitis or Crohn’s disease

Takeda Pharmaceutical Company Limited  today announced that the European Commission has granted a Marketing Authorization for the subcutaneous (SC) formulation of Entyvio(vedolizumab), a gut-selective biologic for use as maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) or Crohn’s disease (CD). Entyvio SC will be made available in both a pre-filled syringe and a pre-filled pen.

UC and CD are two of the most common forms of inflammatory bowel disease (IBD) and affect more than two million people in Europe.1,2 This decision by the European Commission means that EntyvioSC is now approved for use in the 27 member states of the European Union, plus the United Kingdom, Norway, Liechtenstein and Iceland.

“We are delighted that the European Commission has approved the subcutaneous formulation of Entyvio. This allows physicians and adult patients to choose the delivery method that works best for each individual patient,” said Adam Zaeske, Head, GI Franchise, Europe and Canada Business Unit, Takeda. “Takeda’s commitment to treating gastrointestinal disease means that we are always looking to innovate to provide further therapeutic options to better meet the needs of the patients we serve.”

The European Commission approval was based on the pivotal phase 3 VISIBLE trials which assessed the safety and efficacy of a SC formulation of Entyvio as maintenance therapy in adult patients with moderately to severely active UC or CD who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous (IV) therapy at weeks 0 and 2.3,4,5 Data from an interim analysis of an ongoing, long-term, open-label extension study of patients from VISIBLE 1 and VISIBLE 2 were also considered.6


Takeda strongly believes in the benefit that Entyvio SC can bring to adult patients who live with moderately to severely active UC and CD and remains committed to working with regulatory authorities to bring this important option to patients as quickly as possible. In addition to having received approval from the European Commission, Entyvio SC has been submitted for regulatory review with other regulatory authorities worldwide.

Therapeutic Indications for vedolizumab


Ulcerative colitis
Vedolizumab is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.


Crohn’s disease
Vedolizumab is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.


Important Safety Information for vedolizumab


Contraindications
Hypersensitivity to the active substance or to any of the excipients.


Special warnings and special precautions for use
Intravenous vedolizumab should be administered by a healthcare professional prepared to manage hypersensitivity reactions, including anaphylaxis, if they occur. Appropriate monitoring and medical support measures should be available for immediate use when administering intravenous vedolizumab. Observe patients during infusion and until the infusion is complete.


Infusion-related reactions and Hypersensitivity Reactions
In clinical studies, infusion-related reactions (IRR) and hypersensitivity reactions have been reported, with the majority being mild to moderate in severity. If a severe IRR, anaphylactic reaction, or other severe reaction occurs, administration of vedolizumab must be discontinued immediately and appropriate treatment initiated (e.g., epinephrine and antihistamines). If a mild to moderate IRR occurs, the infusion rate can be slowed or interrupted and appropriate treatment initiated (e.g., epinephrine and antihistamines). Once the mild or moderate IRR subsides, continue the infusion. Physicians should consider pre-treatment (e.g., with antihistamine, hydrocortisone and/or paracetamol) prior to the next infusion for patients with a history of mild to moderate IRR to vedolizumab, in order to minimize their risks.


Infections
Vedolizumab is a gut-selective integrin antagonist with no identified systemic immunosuppressive activity. Physicians should be aware of the potential increased risk of opportunistic infections or infections for which the gut is a defensive barrier. Vedolizumab treatment is not to be initiated in patients with active, severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections until the infections are controlled, and physicians should consider withholding treatment in patients who develop a severe infection while on chronic treatment with vedolizumab. Caution should be exercised when considering the use of vedolizumab in patients with a controlled chronic severe infection or a history of recurring severe infections. Patients should be monitored closely for infections before, during and after treatment. Before starting treatment with vedolizumab, screening for tuberculosis may be considered according to local practice. Some integrin antagonists and some systemic immunosuppressive agents have been associated with progressive multifocal leukoencephalopathy (PML), which is a rare and often fatal opportunistic infection caused by the John Cunningham (JC) virus. By binding to the α4β7 integrin expressed on gut-homing lymphocytes, vedolizumab exerts an immunosuppressive effect specific to the gut. No systemic immunosuppressive effect was noted in healthy subjects. Healthcare professionals should monitor patients on vedolizumab for any new onset or worsening of neurological signs and symptoms, and consider neurological referral if they occur. If PML is suspected, treatment with vedolizumab must be withheld; if confirmed, treatment must be permanently discontinued. Typical signs and symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body, clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. The progression of deficits usually leads to death or severe disability over weeks or months.


Malignancies
The risk of malignancy is increased in patients with ulcerative colitis and Crohn’s disease. Immunomodulatory medicinal products may increase the risk of malignancy.


Prior and concurrent use of biological products
No vedolizumab clinical trial data are available for patients previously treated with natalizumab. No clinical trial data for concomitant use of vedolizumab with biologic immunosuppressants are available. Therefore, the use of vedolizumab in such patients is not recommended.


Vaccinations
Prior to initiating treatment with vedolizumab all patients should be brought up to date with all recommended immunizations. Patients receiving vedolizumab may receive non-live vaccines (e.g., subunit or inactivated vaccines) and may receive live vaccines only if the benefits outweigh the risks.


Adverse reactions include: nasopharyngitis, headache, arthralgia, upper respiratory tract infection, bronchitis, influenza, sinusitis, cough, oropharyngeal pain, nausea, rash, pruritus, back pain, pain in extremities, pyrexia, fatigue, injection site reactions and anaphylaxis.

Tags : #CrohnsDisease #Vedolizumab #EuropeanCommission

About the Author


Team Medicircle

Related Stories

22 Feb

Is the World on the Brink of Another Pandemic? Scientists Discover a New Bat Virus

The discovery highlights the constant threat posed by emerging infectious diseases and the need for proactive global health strategies.

View
22 Feb

Will India’s Healthcare Budget Support a Future of Robotic Surgeries?

With government support, growing market investment, and ongoing technological advancements, robotic surgery is set to transform the way medical procedures are performed in India.

View
21 Feb

Young India’s Health Crisis: Why Insurance Claims Are Rising Among 25-35 Year Olds

As healthcare costs continue to rise, employees must choose policies wisely, while companies need to offer customized, flexible, and proactive health insurance plans that address the evolving needs of today’s workforce.

View
21 Feb

Foreign Medical Aspirants in Trouble: NMC’s Warning on Pending Eligibility Certificates

Understanding and following the right procedures can save years of uncertainty, legal battles, and career roadblocks.

View
21 Feb

Odisha’s Bold Healthcare Vision: A Rs 12,000 Crore Blueprint for Universal Health Access

The ambitious policies outlined in this budget signal a new era of healthcare reforms, ensuring that no citizen is denied medical treatment due to financial or geographical constraints.

View
21 Feb

India vs. Trump’s Pharma Tariff: The Battle Over Affordable Medicine

Indian pharmaceutical companies may suffer short-term financial setbacks, but they hold the upper hand, because the U.S. needs Indian generics more than India needs the U.S. market.

View
20 Feb

Is Your Home’s Air Poisoning You? Shocking New Study Reveals Hidden Indoor Pollution Risks

By taking simple steps to reduce pollutants and enhance ventilation, you can create a safer, healthier environment inside your home

View
19 Feb

Public Hospitals Go High-Tech: AIIMS Delhi Leads India’s Robotic Surgery Wave

AIIMS sets a precedent for other hospitals across India to follow. If robotic surgery becomes more widespread, the dream of world-class healthcare for all Indians may not be as distant as it once seemed.

View
27 Nov

Breakfast Wars: Why Men and Women Should Eat Differently

As we continue to uncover the science behind how our bodies process food, it becomes clear that what works for one person may not work for another.

View
08 Jun

Guarding Little Minds: Omega-3 Emulsion Shields Newborn Brains

The effectiveness of the experimental emulsion may be attributed to its faster absorption into the bloodstream, occurring twice as quickly as the commercial emulsion.

View

-Advertisements-




Trending Now

Will India’s Healthcare Budget Support a Future of Robotic Surgeries?February 22, 2025
Is the World on the Brink of Another Pandemic? Scientists Discover a New Bat VirusFebruary 22, 2025
Newcastle University Expands Academic and Research Collaborations in IndiaFebruary 21, 2025
Get Ready to #BibaUp! Kriti Sanon Unveils the Season’s Most Stylish Summer CollectionFebruary 21, 2025
A Rare Condition: Surgery Saves 2-Day-Old Baby as Organs Shift Into ChestFebruary 21, 2025
Odisha’s Bold Healthcare Vision: A Rs 12,000 Crore Blueprint for Universal Health AccessFebruary 21, 2025
Young India’s Health Crisis: Why Insurance Claims Are Rising Among 25-35 Year OldsFebruary 21, 2025
India vs. Trump’s Pharma Tariff: The Battle Over Affordable MedicineFebruary 21, 2025
Foreign Medical Aspirants in Trouble: NMC’s Warning on Pending Eligibility CertificatesFebruary 21, 2025
Think Your Work Music Helps You Focus? Science Says Think AgainFebruary 21, 2025
Is Your Home’s Air Poisoning You? Shocking New Study Reveals Hidden Indoor Pollution RisksFebruary 20, 2025
The Society of Automotive Engineers & B V Raju Institution of Technology; to host the globally prestigious E-BAJA 2025; at Hyderabad!February 20, 2025
Eat right for your heart to beat rightFebruary 19, 2025
Aakash Healthcare and Medtronic Inaugurate North India’s First Dedicated Vein ClinicFebruary 19, 2025
Urgent and accelerated HIV service delivery with equity and rights is critical to end AIDSFebruary 19, 2025
Fasting Fad or Future Health Threat? Why Teens Should Think Twice Before Intermittent Fasting February 19, 2025
Public Hospitals Go High-Tech: AIIMS Delhi Leads India’s Robotic Surgery WaveFebruary 19, 2025
Screen Time and Healthy Habits: Navigating Optimal Development in ChildrenFebruary 18, 2025
SRM Global Hospitals Launches WOW, a Centre Exclusively for Women’s Health and WellnessFebruary 18, 2025
The Hidden Dangers of Scented Candles: Aesthetic Bliss or Silent Health Hazard?February 18, 2025